Author:
Fusco Nicola,Venetis Konstantinos
Publisher
Springer International Publishing
Reference72 articles.
1. (2017). cBioPortal for Cancer Genomics [online]. Available at: http://www.cbioportal.org/. (Published online August 18, 2021). Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy [online]. Available at: https://diagnostics.roche.com/global/en/news-listing/2021/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-dmmr-solid-tumour-patients-eligible-for-anti-pd1-immunotherapy.html. (Published online February 22, 2022.). U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for KEYTRUDA® (pembrolizumab) to Identify Patients with Microsatellite Instability-High (MSI-H) Solid Tumors [online]. Available at: https://ascopost.com/news/february-2022/fda-approves-foundationone-cdx-as-a-companion-diagnostic-for-pembrolizumab-to-identify-patients-with-msi-h-solid-tumors/
2. Albayrak A et al (2020) Clinical pan-cancer assessment of mismatch repair deficiency using tumor-only, targeted next-generation sequencing. JCO Precis Oncol (4):1084–1097
3. André T et al (2020) Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 383(23):2207–2218
4. Andreev-Drakhlin A et al (2021) Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). J Clin Oncol 39(6_suppl):487–487
5. Backes FJ et al (2019) Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: a prognostic biomarker. Cancer 125(3):398–405